Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients

Atherosclerosis

Volumn 207, Issue 1, 2009, Pages 250-254

  Bongers, T N ^a   de Bruijne, E L E ^a,b   Dippel, D W J ^a   de Jong, A J ^a   Deckers, J W ^a   Poldermans, D ^a   de Maat, M P M ^a   Leebeek, F W G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RED CROSS HOSPITAL   (Netherlands)

Author keywords

ADAMTS13; Arterial thrombosis; Cardiovascular diseases; Genetics; VWF

Indexed keywords

VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTERY DISEASE; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADAM PROTEINS; ADULT; AGE FACTORS; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CORONARY DISEASE; DOWN-REGULATION; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PERIPHERAL VASCULAR DISEASES; PHENOTYPE; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 70350566703     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.04.013     Document Type: Article

References (24)

1. Levy G.G., Nichols W.C., Lian E.C., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413 (2001) 488-494
2. Levy G.G., Motto D.G., and Ginsburg D. ADAMTS13 turns 3. Blood 106 (2005) 11-17
3. Zheng X., Majerus E.M., and Sadler J.E. ADAMTS13 and TTP. Curr Opin Hematol 9 (2002) 389-394
4. Soejima K., Mimura N., Hirashima M., et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem (Tokyo) 130 (2001) 475-480
5. Plaimauer B., Fuhrmann J., Mohr G., et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 107 (2006) 118-125
6. Bongers T.N., De Maat M.P., Dippel D.W., Uitterlinden A.G., and Leebeek F.W. Absence of Pro475Ser polymorphism in ADAMTS-13 in Caucasians. J Thromb Haemost 3 (2005) 805
7. Dong J.F. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 3 (2005) 1710-1716
8. Chauhan A.K., Motto D.G., Lamb C.B., et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 203 (2006) 767-776
9. Moake J.L. Thrombotic microangiopathies. N Engl J Med 347 (2002) 589-600
10. Chion C.K., Doggen C.J., Crawley J.T., Lane D.A., and Rosendaal F.R. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 109 (2007) 1998-2000
11. Kaikita K., Soejima K., Matsukawa M., Nakagaki T., and Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost 4 (2006) 2490-2493
12. Marenberg M.E., Risch N., Berkman L.F., Floderus B., and de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 330 (1994) 1041-1046
13. Vaartjes I., van Dis S.J., Peters R.J.G., Visseren F.L.J., and Bots M.L. Hart- en vaatziekten in Nederland naar geslacht. In: Vaartjes I., Peters R.J.G., van Dis S.J., and Bots M.L. (Eds). Hart- en vaatziekten in Nederland 2008, cijfers over ziekte en sterfte. (2008), Nederlandse Hartstichting, Den Haag pp. 9-22.
14. Dormandy J.A., and Rutherford R.B. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 31 (2000) S1-S296
15. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., and Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70 (2002) 425-434
16. Bongers T.N., de Maat M.P., van Goor M.L., et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 37 (2006) 2672-2677
17. Folsom A.R., Rosamond W.D., Shahar E., et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 100 (1999) 736-742
18. Whincup P.H., Danesh J., Walker M., et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 23 (2002) 1764-1770
19. van der Meer I.M., Brouwers G.J., Bulk S., et al. Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol 124 (2004) 343-347
20. Spiel A.O., Gilbert J.C., and Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 117 (2008) 1449-1459
21. Crawley J.T., Lane D.A., Woodward M., Rumley A., and Lowe G.D. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 6 (2008) 583-588
22. Mannucci P.M., Capoferri C., and Canciani M.T. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol 126 (2004) 213-218
23. Feys H.B., Canciani M.T., Peyvandi F., et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 138 (2007) 534-540
24. Kokame K., Matsumoto M., Soejima K., et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 99 (2002) 11902-11907